PLx Pharma Inc
NASDAQ:PLXP
Relative Value
There is not enough data to reliably calculate the relative value of PLXP.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
PLXP Competitors Multiples
PLx Pharma Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
PLx Pharma Inc
NASDAQ:PLXP
|
116.6k USD | 0 | -0 | 0.4 | 0.4 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
731.8B USD | 20.4 | 119.2 | 58.4 | 66.4 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 16.5 | 45.1 | 33.6 | 36.9 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
372.2B USD | 4.3 | 9.7 | 11.9 | 15.6 | ||
US |
Merck & Co Inc
NYSE:MRK
|
332.3B USD | 5.4 | 144.1 | 35.9 | 58.5 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
187.7B GBP | 5 | 37.6 | 174.5 | 278.3 | ||
CH |
Roche Holding AG
SIX:ROG
|
189B CHF | 3.2 | 16.4 | 9.3 | 11 | ||
CH |
Novartis AG
SIX:NOVN
|
182.7B CHF | 3.4 | 11.5 | 8.7 | 12.7 | ||
US |
Pfizer Inc
NYSE:PFE
|
161.7B USD | 2.9 | -523.3 | 12.9 | 20.6 |